Comparing the long-term cost-effectiveness of repaglinide plus metformin versus nateglinide plus metformin in type 2 diabetes patients with inadequate glycaemic control: An application of the CORE diabetes model in type 2 diabetes

Current Medical Research and Opinion

Volumn 20, Issue SUPPL. 1, 2004, Pages

  Palmer, Andrew J ^a   Roze, Stéphane ^a   Lammert, Morten ^a   Valentine, William J ^a   Minshall, Michael E ^b   Nicklasson, Lars ^c   Gall, Mari Anne ^d   Spinas, Giatgen A ^e  

^a IQVIA   (United States)

^b CORE USA LLC ^*  (United States)

^c NOVO NORDISK INC   (United States)

^d NOVO NORDISK A S   (Denmark)

^e UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Complications, costs; Cost effectiveness; HbA1c; Metformin; Modelling; Nateglinide; Repaglinide; Type 2 diabetes

Indexed keywords

GLIBENCLAMIDE; HEMOGLOBIN A1C; METFORMIN; NATEGLINIDE; REPAGLINIDE; SULFONYLUREA;

ARTICLE; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DOSE RESPONSE; HEALTH ECONOMICS; LIFE EXPECTANCY; LONG TERM CARE; MEDICARE; MONTE CARLO METHOD; NON INSULIN DEPENDENT DIABETES MELLITUS; QUALITY ADJUSTED LIFE YEAR; RELIABILITY; TREATMENT OUTCOME;

CARBAMATES; COHORT STUDIES; COMPUTER SIMULATION; COST OF ILLNESS; COST-BENEFIT ANALYSIS; CYCLOHEXANES; DECISION SUPPORT SYSTEMS, CLINICAL; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; HEALTH CARE COSTS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; METFORMIN; MIDDLE AGED; MODELS, ECONOMETRIC; OUTCOME ASSESSMENT (HEALTH CARE); PHENYLALANINE; PIPERIDINES; QUALITY-ADJUSTED LIFE YEARS;

EID: 5344281097     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079904X2015     Document Type: Article

References (45)

1. Jonsson B. The economic impact of diabetes. Diabetes Care 1998; 21 Suppl 3:C7-10.
2. Guo JJ, Gibson JT, Gropper DM, Oswald SL, Barker KN. Empiric investigation on direct costs-of-illness and healthcare utilization of Medicaid patients with diabetes mellitus. Am J Manag Care 1998; 4(10):1433-46.
3. Killilea T. Long-term consequences of type 2 diabetes mellitus: economic impact on society and managed care. Am J Manag Care 2002; 8(16 Suppl):S441-S449.
4. Rubin RJ, Altman WM, Mendelson DN. Health care expenditures for people with diabetes mellitus, 1992. J Clin Endocrinol Metab 1994; 78:809A-F.
5. Brandle M, Zhou H, Smith BR, Marriott D, Burke R, Tabaei BP, Brown MB, Herman WH. The direct medical cost of type 2 diabetes. Diabetes Care 2003;26(8):2300-4.
6. CCOHTA. Canadian Coordinating Office for Health Technology Assessment. Guidelines for economic evaluations of pharmaceuticals: Canada. 2 ed. Ottowa: CCOHTA, 1997.
7. NICE. National Institute for Clinical Excellence. Guide to the technology appraisal proccess. Available online at http://www.nice.org.uk/pdf/ technologyappraisalprocessfinal.pdf (last accessed 4 July 2002).
8. PBAC. Pharmaceutical Benefits Advisory Committee. Guidelines for the pharmaceutical industry on preparation of submissions to the PBAC, 2002. Available online at http://www.health.gov.au/pbs/pubs/pharmpac/gusubpac.htm (last accessed 7 July 2002).
9. Sullivan SD, Lyles A, Luce B et al. AMCP guidelines for submission of clinical and economic evaluation data to support formulary listing in the US health plans and pharmacy benefits management organizations. J Managed Care Pharm 2001; 7:272-82.
10. Detsky AS. Using cost-effectiveness analysis for formulary decision making: from theory into practice. Pharmacoeconomics 1994; 6(4):281-8.
11. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA 1996; 276(15):1253-8.
12. Detsky AS, Naglie G, Krahn MD, Naimark D, Redelmeier DA. Primer on medical decision analysis: Part 1 - Getting started. Med Decis Making 1997; 17(2):123-5.
13. Detsky AS, Naglie G, Krahn MD, Redelmeier DA, Naimark D. Primer on medical decision analysis: Part 2 - Building a tree. Med Decis Making 1997; 17(2):126-35.
14. Stockl K, Vanderplas AM, Nicklasson L. A comparison of costs for four oral antidiabetic regimens within a managed care population. Manag Care Interface 2003; 16(7):31-6.
15. Ramsdell JW, Braunstein SN, Stephens JM, Bell CF, Botteman MF, Devine ST. Economic model of first-line drug strategies to achieve recommended glycaemic control in newly diagnosed type 2 diabetes mellitus. Pharmacoeconomics 2003; 21(11):819-37.
16. Salas M, Ward A, Caro J. Health and economic effects of adding nateglinide to metformin to achieve dual control of glycosylated hemoglobin and postprandial glucose levels in a model of type 2 diabetes mellitus. Clin Ther 2003; 24(10):1690-1705.
17. Palmer AJ, Roze S, Valentine WJ, Minshall ME, Foos V, Lurati FM, Lammert M, Spinas GA. The CORE Diabetes Model: projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. Curr Med Res Opin 2004; 20(Suppl 1):S5-S26.
18. Palmer AJ, Roze S, Valentine WJ, Minshall ME, Foos V, Lurati FM, Lammert M, Spinas GA. Validation of the CORE Diabetes Model against epidemiological and clinical studies. Curr Med Res Opin 2004; 20(Suppl 1):S27-S40.
19. Stevens RJ, Kothari V, Adler AI, Stratton IM. The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56). Clin Sci (Lond) 2001; 101(6):671-9.
20. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321(7258):405-12.
21. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348(5):383-93.
22. UKPDS Group. Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352:854-65.
23. UKPDS Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352:837-53.
24. Turner RC, Cull CA, Frighi V and Holman RR for the UKPDS Group. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes. Progressive requirement for multiple therapies (UKPDS 49). JAMA 1999; 281(21):2005-12.
25. Landgraf R. Meglitinide analogues in the treatment of type 2 diabetes mellitus. Drugs Aging 2000; 17(5):411-25.
26. Raskin P, Klaff L, McGill J, South SA, Hollander P, Khutoryansky N et al. Efficacy and safety of combination therapy: repaglinide plus metformin versus nateglinide plus metformin. Diabetes Care 2003; 26(7):2063-8.
27. U.S. Department of Labor. Bureau of Labor Statistics. Available online at http://data.bls.gov/cgi-bin/surveymost?cu (last accessed December 9, 2003).
28. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-effectiveness in health and medicine. 1 edn. New York: Oxford University Press, 1996.
29. UKPDS Group. UKPDS 26: sulphonylurea failure in non-insulin-dependent diabetic patients over six years. Diabetic Medicine 1998; 15:297-303.
30. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999; 281(21):2005-12.
31. Baron MA. Comparison of repaglinide and nateglinide in combination with metformin: Response to Raskin et al. Diabetes Care 2003; 26(12):3361-2.
32. Raskin P. Comparison of repaglinide and nateglinide in combination with metformin: Response to Baron. Diabetes Care 2003; 26(12):3362-3.
33. Saad MF, Rosenstock J, Hale P, Khutoryansky N. Repaglinide vs. nateglinide monotherapy: a randomized, multicenter, open-label study (Abstract 44). Endocrine Pract 9 (Suppl. 1): 17. 2003.
34. Klonoff DC, Schwartz DM. An economic analysis of interventions for diabetes. Diabetes Care 2000; 23(3):390-404.
35. Harris MI, Cowie CC, Stern MP. Diabetes in America. 2nd edn. Bethesda, Md.: National Institute of Diabetes and Digestive and Kidney Diseases, 1995. (NIH publication no. 95-1468). 1995.
36. Nichols GA, Hillier TA, Erbey JR, Brown JB. Congestive heart failure in type 2 diabetes: prevalence, incidence, and risk factors. Diabetes Care 2001; 24(9):1614-19.
37. Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol 1998; 82(8A):2N-9N.
38. Phillips SJ, Whisnant JP, O'Fallon WM, Frye RL. Prevalence of cardiovascular disease and diabetes mellitus in residents of Rochester, Minnesota. Mayo Clin Proc 1990; 65(3):344-59.
39. Miller CD, Phillips LS, Tate MK, Porwoll JM, Rossman SD, Cronmiller N et al. Meeting American Diabetes Association guidelines in endocrinologist practice. Diabetes Care 2000; 23(4):444-8.
40. Brandle M, Zhou H, Smith BR, Marriott D, Burke R, Tabaei BP et al. The direct medical cost of type 2 diabetes. Diabetes Care 2003; 26(8):2300-4.
41. Moss SE, Klein R, Klein BE. The prevalence and incidence of lower extremity amputation in a diabetic population. Arch Intern Med 1992; 152(3):610-16.
42. Harris MI. Health care and health status and outcomes for patients with type 2 diabetes. Diabetes Care 2000; 23(6):754-8.
43. Hueston WJ, Scibelli S, Mainous III AG. Use of microalbuminuria testing in persons with type 2 diabetes: are the right patients being tested? J Fam Pract 2001; 50(8):669-73.
44. Massing MW, Foley KA, Sueta CA, Chowdhury M, Biggs DP, Alexander CM et al. Trends in lipid management among patients with coronary artery disease: has diabetes received the attention it deserves? Diabetes Care 2003; 26(4):991-7.
45. McFarlane SI, Jacober SJ, Winer N, Kaur J, Castro JP, Wui MA et al. Control of cardiovascular risk factors in patients with diabetes and hypertension at urban academic medical centers. Diabetes Care 2002; 25(4):718-23.